Skip to content
10-Q

Quarterly Report

APELLIS PHARMACEUTICALS, INC.

0000950170-24-121062

← back to feed
Filed
Nov 5, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 29, 2024 124.39M sh
Current Liabilities Q3 2024 · Sep 30, 2024 $191.26M
Current Liabilities Q3 2024 · Dec 31, 2023 $247.59M
Total Liabilities Q3 2024 · Sep 30, 2024 $664.75M
Total Liabilities Q3 2024 · Dec 31, 2023 $594.21M
Current Assets Q3 2024 · Sep 30, 2024 $833.9M
Current Assets Q3 2024 · Dec 31, 2023 $766.33M
Total Assets Q3 2024 · Sep 30, 2024 $901.87M
Total Assets Q3 2024 · Dec 31, 2023 $788.73M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $351.19M
Cash And Equivalents Q3 2024 · Sep 30, 2023 $452.41M
Shares Diluted restated Q3 2024 · Sep 30, 2023 120.29M sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 117.83M sh
Capex Q3 2024 · Sep 30, 2023 $678K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$496.86M
Stockholders Equity Q3 2024 · Sep 30, 2023 $232.27M
Stockholders Equity Q3 2024 · Jun 30, 2023 $345.4M
Stockholders Equity Q3 2024 · Mar 31, 2023 $412.12M
Stockholders Equity Q3 2024 · Dec 31, 2022 $169.87M
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.17
Eps Diluted Q3 2024 · Sep 30, 2023 −$3.73
Eps Basic Q3 2024 · Sep 30, 2023 −$1.17
Eps Basic Q3 2024 · Sep 30, 2023 −$3.73
Sga Expense Q3 2024 · Sep 30, 2023 $145.65M
Sga Expense Q3 2024 · Sep 30, 2023 $359.11M
Rd Expense Q3 2024 · Sep 30, 2023 $79.42M
Rd Expense Q3 2024 · Sep 30, 2023 $285.11M
Net Income Q3 2024 · Sep 30, 2023 −$140.24M
Net Income Q3 2024 · Sep 30, 2023 −$440.05M
Net Income Q3 2024 · Jun 30, 2023 −$122.04M
Net Income Q3 2024 · Mar 31, 2023 −$177.78M
Operating Income Q3 2024 · Sep 30, 2023 −$137.08M
Operating Income Q3 2024 · Sep 30, 2023 −$432.6M
Revenue Q3 2024 · Sep 30, 2023 $110.4M
Revenue Q3 2024 · Sep 30, 2023 $250.21M